Form SCHEDULE 13G - Statement of Beneficial Ownership by Certain Investors:
SEC Accession No. 0000950170-25-021487
Filing Date
2025-02-14
Accepted
2025-02-14 17:24:21
Documents
2

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G  
1 primary_doc.xml SCHEDULE 13G 15709
2 EX-99.1 ck0001669811-ex99_1.pdf EX-99.1 80419
  Complete submission text file 0000950170-25-021487.txt   128559
Mailing Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248
Business Address 16000 DALLAS PARKWAY SUITE 800 DALLAS TX 75248 214.866.0202
Anson Funds Management LP (Filed by) CIK: 0001491072 (see all company filings)

EIN.: 300134498 | State of Incorp.: TX | Fiscal Year End: 1231
Type: SCHEDULE 13G

Mailing Address 265 JINGJIU AVENUE JINGGANGSHAN ECON. AND TECH. DEV. ZONE JI'AN, JIANGXI F4 343100
Business Address 265 JINGJIU AVENUE JINGGANGSHAN ECON. AND TECH. DEV. ZONE JI'AN, JIANGXI F4 343100 86-0796-8403309
Universe Pharmaceuticals INC (Subject) CIK: 0001809616 (see all company filings)

EIN.: 000000000 | State of Incorp.: F4 | Fiscal Year End: 0930
Type: SCHEDULE 13G | Act: 34 | File No.: 005-93205 | Film No.: 25631099
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)